--- title: "Corcept Therapeutics (NASDAQ:CORT) Director James Wilson Sells 10,000 Shares of Stock" type: "News" locale: "en" url: "https://longbridge.com/en/news/296332659.md" description: "Corcept Therapeutics Director James Wilson sold 10,000 shares on August 14 at $111.43, totaling $1.11 million. Post-transaction, he holds 1,074,543 shares valued at ~$119.7 million, a 0.92% ownership decrease. The sale was filed with the SEC." datetime: "2026-08-19T09:38:04.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/296332659.md) - [en](https://longbridge.com/en/news/296332659.md) - [zh-HK](https://longbridge.com/zh-HK/news/296332659.md) generator: "portal-rs" --- # Corcept Therapeutics (NASDAQ:CORT) Director James Wilson Sells 10,000 Shares of Stock Corcept Therapeutics Incorporated (NASDAQ:CORT - Get Free Report) Director James Wilson sold 10,000 shares of the stock in a transaction dated Friday, August 14th. The shares were sold at an average price of $111.43, for a total value of $1,114,300.00. Following the completion of the sale, the director owned 1,074,543 shares of the company's stock, valued at approximately $119,736,326.49. This trade represents a 0.92% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. ## Corcept Therapeutics Stock Performance - 3 Biopharmaceutical Stocks Bucking the Sell-Off Shares of CORT stock opened at $118.10 on Wednesday. Corcept Therapeutics Incorporated has a fifty-two week low of $28.66 and a fifty-two week high of $122.21. The firm has a market capitalization of $12.77 billion, a price-to-earnings ratio of 281.20 and a beta of 0.45. The stock's 50-day simple moving average is $95.03 and its 200-day simple moving average is $63.09. Corcept Therapeutics (NASDAQ:CORT - Get Free Report) last announced its quarterly earnings data on Wednesday, July 29th. The biotechnology company reported $0.36 EPS for the quarter, beating the consensus estimate of $0.02 by $0.34. The firm had revenue of $256.15 million during the quarter, compared to analyst estimates of $221.15 million. Corcept Therapeutics had a net margin of 6.52% and a return on equity of 8.26%. Corcept Therapeutics's revenue was up 31.7% on a year-over-year basis. During the same period last year, the firm posted $0.29 EPS. As a group, equities analysts forecast that Corcept Therapeutics Incorporated will post 1.13 earnings per share for the current year. ## Analyst Ratings Changes * * * * * * Several equities research analysts have recently commented on CORT shares. Zacks Research upgraded shares of Corcept Therapeutics from a "strong sell" rating to a "hold" rating in a research note on Monday, May 4th. Wolfe Research downgraded Corcept Therapeutics from a "peer perform" rating to an "underperform" rating and set a $50.00 target price on the stock. in a research report on Monday, July 27th. Weiss Ratings restated a "hold (c-)" rating on shares of Corcept Therapeutics in a research note on Wednesday, June 24th. Wall Street Zen raised Corcept Therapeutics from a "hold" rating to a "strong-buy" rating in a research report on Saturday, August 1st. Finally, UBS Group set a $135.00 price target on Corcept Therapeutics in a research note on Thursday, May 28th. Five equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Corcept Therapeutics currently has a consensus rating of "Moderate Buy" and an average target price of $138.17. **Read Our Latest Analysis on CORT** ## Institutional Trading of Corcept Therapeutics Several large investors have recently made changes to their positions in the business. Torren Management LLC purchased a new position in shares of Corcept Therapeutics during the fourth quarter worth $25,000. Advisory Services Network LLC purchased a new stake in Corcept Therapeutics in the third quarter valued at $25,000. Mitsubishi UFJ Asset Management Co. Ltd. acquired a new stake in Corcept Therapeutics during the 2nd quarter worth about $27,000. Atlas Capital Advisors Inc. acquired a new stake in Corcept Therapeutics during the 4th quarter worth about $31,000. Finally, State of Wyoming raised its stake in shares of Corcept Therapeutics by 29.5% during the 1st quarter. State of Wyoming now owns 816 shares of the biotechnology company's stock valued at $33,000 after buying an additional 186 shares during the last quarter. 93.61% of the stock is owned by hedge funds and other institutional investors. ## About Corcept Therapeutics (Get Free Report) Corcept Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing drugs that modulate the effects of cortisol, a hormone implicated in a range of severe metabolic, oncologic and psychiatric disorders. The company's scientific platform centers on selectively targeting the glucocorticoid receptor to counteract the harmful consequences of excess cortisol, a strategy designed to address diseases with significant unmet medical needs. The company's flagship marketed product, Korlym (mifepristone), is approved in the United States for the treatment of hyperglycemia secondary to Cushing's syndrome in patients who have type 2 diabetes or glucose intolerance and are not candidates for surgery. ## Featured Stories - Five stocks we like better than Corcept Therapeutics - The AI Boom Is Turning This Cable Maker Into a Stock to Watch - A Star Investor Just Trimmed Amazon—Here's What It means - Wendy’s Deal Buzz May Give Fast-Food Investors a New Reason to Look - Home Depot Analysts See a Path to $375 and Beyond *This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to \[email protected\].* Insider Buying or Selling at Corcept Therapeutics? Sign-up to receive InsiderTrades.com's daily insider buying and selling report for Corcept Therapeutics and related companies. From Our Partners ALERT: Drop these 5 stocks before the market opens tomorrow! The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc... Weiss Ratings Louis Navellier: My #1 AI stock for 2026 (name & ticker inside) Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top... InvestorPlace Ready to give options a try? Your first trade (Ticker included) -INSIDE Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st... Base Camp Trading They didn't warn anyone in 1971. This time someone is warning you. On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb... Reagan Gold Group Small Colorado Company (Backed by Sam Altman) Could Save U.S. Power Grid A small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c... Altimetry Iran War Shock: What I Was Told In That Private Meeting You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th... Banyan Hill Publishing My top 3 AI picks for the next decade Alexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A... The Oxford Club Buy this stock today Marc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo... Chaikin Analytics ### Related Stocks - [CORT.US](https://longbridge.com/en/quote/CORT.US.md) - [UBS.US](https://longbridge.com/en/quote/UBS.US.md) - [8306.JP](https://longbridge.com/en/quote/8306.JP.md) - [MUFG.US](https://longbridge.com/en/quote/MUFG.US.md) - [AMZN.US](https://longbridge.com/en/quote/AMZN.US.md) - [WEN.US](https://longbridge.com/en/quote/WEN.US.md) ## Related News & Research - [Insider Selling: Corcept Therapeutics (NASDAQ:CORT) Director Sells $12,251,409.50 in Stock](https://longbridge.com/en/news/296607178.md) - [BlackRock Inc. Makes New $1.08 Billion Investment in Corcept Therapeutics Incorporated $CORT](https://longbridge.com/en/news/296675400.md) - [Corcept Chief Business Officer Gary Charles Robb sells 10,000 shares for $1.16 million](https://longbridge.com/en/news/296267228.md) - [Corcept Therapeutics director David L. Mahoney sells 103,606 shares worth $12.26 million](https://longbridge.com/en/news/296533256.md) - [Corcept Therapeutics (CORT) Stock Could Be Undervalued Despite Mixed Broader Checks](https://longbridge.com/en/news/295147113.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**